Longer RFS with Nivolumab Than with Ipilimumab Among Patients with Resected Stage IIIB-C or Stage IV Melanoma By Ogkologos - February 2, 2026 74 0 Facebook Twitter Google+ Pinterest WhatsApp Final data from the CheckMate 238 study Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR ΣΑΡΚΩΜΑ February 7, 2019 One Million Masks Donated! But GreaterGood Will Continue to Help Where... October 5, 2020 ΚΑΡΚΙΝΟΣ ΤΟΥ ΝΕΦΡΟΥ February 10, 2019 New Blood Test Can Screen For Over 50 Cancers June 7, 2021 Load more HOT NEWS News digest – larger waistlines and prostate cancer, GP gut instincts... Early Signs of Efficacy of New Targeted Agents and Immunotherapies Reported... FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph for Subcutaneous Injection FDA Approves Entrectinib Based on Tumor Genetics Rather Than Cancer Type
